Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk of Death in Patients with High-Risk TNBC By Ogkologos - September 9, 2025 417 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the A-BRAVE study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Pediatric MATCH Study Finds More Targetable Genetic Changes than Expected May 16, 2019 Getting cancer services back on track during the COVID-19 pandemic June 22, 2020 Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable... August 28, 2025 Ability of Deep Learning to Accurately Diagnose Frequent STS Subtypes from... August 26, 2021 Load more HOT NEWS Addressing Racial Disparities in Cancer Care: “Your Stories” Podcast Sacituzumab Govitecan Plus Pembrolizumab Demonstrate Encouraging Activity in Patients with mUC... Combined MRI-directed and Standard Biopsy in Men With Elevated PSA and... HER2 Is Not a Predictive Biomarker of Benefit From Up-front Chemotherapy...
